Memórias do Instituto Oswaldo Cruz

ANTITRYPANOSOMATID DRUGS

testeira drugs 2022

To celebrate the event and the creation of the International Consortium of Trypanocidal and Leishmanicidal Drugs,
13 perspective articles were written by different Brazilian specialists, discussing promising alternative therapeutic approaches/strategies to combat Chagas disease and leishmaniasis.

EDITORIAL | Molecular mechanisms of action of trypanocidal and leishmanicidal drugs with focus on novel chemotherapeutic strategies: creation of a Brazilian multicentre working group Rubem Figueiredo Sadok Menna-Barreto, André Luis Souza dos Santos DOI: 10.1590/0074-02760220002

Translational research in Chagas disease: perspectives in nutritional therapy emerging from selenium supplementation studies as a complementary treatment Tania C de Araujo-Jorge, Roberto R Ferreira DOI: 10.1590/0074-0276220001

Perspectives for a new drug candidate for Chagas disease therapy Maria de Nazaré Correia Soeiro DOI: 10.1590/0074-02760220004

Proteolytic inhibitors as alternative medicines to treat trypanosomatid-caused diseases: experience with calpain inhibitors Vítor Ennes-Vidal, André Luis Souza dos Santos, Marta Helena Branquinha, Claudia Masini d’Avila-Levy DOI: 10.1590/0074-02760220017

Multi-therapeutic strategy targeting parasite and inflammation-related alterations to improve prognosis of chronic Chagas cardiomyopathy: a hypothesis-based approach* Joseli Lannes-Vieira DOI: 10.1590/0074-02760220019

Is the mitochondrion a promising drug target in trypanosomatids? Yasmin Pedra-Rezende, Ana Cristina Souza Bombaça, Rubem Figueiredo Sadok Menna-Barreto DOI: 10.1590/0074-02760210379

Computational approaches towards the discovery and optimisation of cruzain inhibitors Viviane Corrêa Santos, Rafaela Salgado Ferreira DOI: 10.1590/0074-02760210385

Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors Leandro Stefano Sangenito, Claudia Masini d’Avila-Levy, Marta Helena Branquinha, André Luis Souza dos Santos DOI: 10.1590/0074-02760210386

Transforming growth factor-β as a therapeutic target for the cardiac damage of Chagas disease Mariana Caldas Waghabi, Roberto Rodrigues Ferreira, Rayane da Silva Abreu, Wim Degrave, Elen Mello de Souza, Sabine Bailly, Jean-Jacques Feige, Tania C de Araújo-Jorge DOI: 10.1590/0074-02760210395

Natural compounds based chemotherapeutic against Chagas disease and leishmaniasis: mitochondrion as a strategic target Danielle Lazarin-Bidóia, Francielle Pelegrin Garcia, Tânia Ueda-Nakamura, Sueli de Oliveira Silva, Celso Vataru Nakamura DOI: 10.1590/0074-02760220396

Antioxidant defence system as a rational target for Chagas disease and Leishmaniasis chemotherapy Ana Maria Murta Santi, Silvane Maria Fonseca Murta DOI: 10.1590/0074-02760210401

Past and future of trypanosomatids high-throughput phenotypic screening Rafael Ferreira Dantas, Eduardo Caio Torres dos Santos, Floriano Paes Silva Junior DOI: 10.1590/0074-02760210402

Antileishmanial metallodrugs and the elucidation of new drug targets linked to post-translational modifications machinery: pitfalls and progress Rubens Lima do Monte Neto, Paulo Otávio Lourenço Moreira, Alessandra Mara de Sousa, Miguel Antonio do Nascimento Garcia, Suellen Rodrigues Maran, Nilmar Silvio Moretti DOI: 10.1590/0074-02760220403

Host cholesterol influences the activity of sterol biosynthesis inhibitors in Leishmania amazonensis Valter Viana Andrade-Neto, Pedro Paulo de Abreu Manso, Miria Gomes Pereira, Nuccia Nicole Theodoro de Cicco, Georgia Corrêa Atella, Marcelo Pelajo-Machado, Rubem Figueiredo Sadok Menna-Barreto, Eduardo Caio Torres-Santos DOI: 10.1590/0074-02760220407

ANTITRYPANOSOMATID DRUGS

Our Location

Support Program

Site Map

ANTITRYPANOSOMATID DRUGS

Our Location

Support Program

Site Map

Member Login